Berlin - Delayed Quote EUR

Ionis Pharmaceuticals Inc (ISI.BE)

26.28

+0.38

+(1.47%)

At close: April 30 at 8:08:25 AM GMT+2

Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Ionis Pharmaceuticals Inc (IONS) reports a 10% revenue increase and raises 2025 guidance, driven by successful product launches and strategic initiatives.

GuruFocus.com 7 hours ago

IONS
Q1 2025 Ionis Pharmaceuticals Inc Earnings Call

Q1 2025 Ionis Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents 8 hours ago

IONS
Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks yesterday

IONS
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 32.43% and 9.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks yesterday

IONS
Ionis Pharmaceuticals: Q1 Earnings Snapshot

The Carlsbad, California-based company said it had a loss of 93 cents per share. Losses, adjusted for stock option expense, were 75 cents per share. The results beat Wall Street expectations.

Associated Press Finance yesterday

IONS
Ionis reports first quarter 2025 financial results

CARLSBAD, Calif., April 30, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the first quarter ended March 31, 2025.

Business Wire yesterday

IONS
New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

CARLSBAD, Calif., April 29, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced results from a new survey showing that 91% of surveyed adults living with hereditary angioedema (HAE) were interested in trying a new prophylactic therapy, with nearly two-thirds (65%) reporting they haven’t yet found the best treatment option for them. The Ionis-sponsored survey was conducted online by The Harris Poll among 150 adults living with HAE and 228 allergists/immunologists who see HAE patients

Business Wire 2 days ago

IONS
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 6 days ago

IONS
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 8 days ago

IONS
Ionis to hold first quarter 2025 financial results webcast

CARLSBAD, Calif., April 16, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30th at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results.

Business Wire 15 days ago

IONS
Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?

Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 21 days ago

IONS

USNA
Ionis to host expert panel discussion on sHTG

CARLSBAD, Calif., April 03, 2025--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet medical needs associated with severe hypertriglyceridemia (sHTG). Key thought leaders in lipidology, cardiology and endocrinology will join Sam Tsimikas, M.D., senior vice president, global cardiovascular development, Ionis, for a live discussion followed by a brief Q&A session.

Business Wire 28 days ago

IONS
Ionis to present at upcoming investor conferences

CARLSBAD, Calif., March 31, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

Business Wire last month

IONS
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

CPRX

IONS
Ionis and Sobi agree on olezarsen commercialisation

Sobi will handle the upcoming regulatory filings and commercialisation in the agreed territories.

Pharmaceutical Technology last month

IONS
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi

In return, Ionis will receive an undisclosed upfront payment from Sobi. It is also eligible to receive milestone payments and a tiered royalty on the drug's future sales.

Zacks last month

IONS
Ionis Partners With Sobi to Commercialize Familial Chylomicronemia Syndrome Treatment Outside US

Ionis Pharmaceuticals (IONS) said Wednesday it has entered into a license agreement with Sobi that a

PREMIUM
MT Newswires last month

IONS
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

CARLSBAD, Calif., March 26, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® receives exclusive rights in countries outside the U.S., Canada and China to commercialize olezarsen as a potential treatment for familial chylomicronemia syndrome (FCS) and severely elevated triglycerides. Ionis will continue to independently commercialize olezarsen in the U.S. Olezarsen was approved by the FDA in December 2024 under the tra

Business Wire last month

IONS
Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stands against other biotech stocks. Biotech Sector Set for Growth Amid Innovation and Investor Interest The biotechnology sector is gaining new momentum with better […]

Insider Monkey last month

IONS
Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

IONS

ZTS

Performance Overview

Return	ISI.BE	S&P 500 (^GSPC)
YTD	-22.75%	-3.90%
1-Year	-32.68%	+12.64%
3-Year	-29.80%	+36.80%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ionis Pharmaceuticals Inc (ISI.BE)

Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Q1 2025 Ionis Pharmaceuticals Inc Earnings Call

Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals: Q1 Earnings Snapshot

Ionis reports first quarter 2025 financial results

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Ionis to hold first quarter 2025 financial results webcast

Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?

Ionis to host expert panel discussion on sHTG

Ionis to present at upcoming investor conferences

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue?

Ionis and Sobi agree on olezarsen commercialisation

IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi

Ionis Partners With Sobi to Commercialize Familial Chylomicronemia Syndrome Treatment Outside US

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts

Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?

Performance Overview